* women who are breastfeeding * recent acute infection defined as: i) any acute infection within 60 days prior to randomization that required hospitalization or treatment with parenteral antibiotics (not covid-19 related) ii) any acute infection within 30 days prior to randomization that required oral antimicrobial or antiviral therapy * history of chronic or recurrent bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, bronchiectasis) * prior exposure to bms-188667 (abatacept) other protocol-defined inclusion/exclusion criteria apply

* women who are breastfeeding * recent acute infection defined as: i) any acute infection within 60 days prior to randomization that required hospitalization or treatment with parenteral antibiotics (not covid-19 related) ii) any acute infection within 30 days prior to randomization that required oral antimicrobial or antiviral therapy * history of chronic or recurrent bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, bronchiectasis) * prior exposure to bms-188667 (abatacept) other protocol-defined inclusion/exclusion criteria apply

- women who are breastfeeding - recent acute infection defined as: i) any acute infection within 60 days prior to randomization that required hospitalization or treatment with parenteral antibiotics (not covid-19 related) ii) any acute infection within 30 days prior to randomization that required oral antimicrobial or antiviral therapy - history of chronic or recurrent bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, bronchiectasis) - prior exposure to bms-188667 (abatacept) other protocol-defined inclusion/exclusion criteria apply

- women who are breastfeeding - recent acute infection defined as: i) any acute infection within 60 days prior to randomization that required hospitalization or treatment with parenteral antibiotics (not covid-19 related) ii) any acute infection within 30 days prior to randomization that required oral antimicrobial or antiviral therapy - history of chronic or recurrent bacterial infection (e.g., chronic pyelonephritis, osteomyelitis, bronchiectasis) - prior exposure to bms-188667 (abatacept) other protocol-defined inclusion/exclusion criteria apply